Juan Luiz Coelho-Silva
Overview
Explore the profile of Juan Luiz Coelho-Silva including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
130
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Hatzlhofer B, Pereira-Martins D, Domingos I, Arcanjo G, Weinhauser I, Falcao D, et al.
Ann Hematol
. 2021 Feb;
100(4):921-931.
PMID: 33586016
Alpha thalassemia and beta-globin haplotype are considered classical genetic disease modifiers in sickle cell anemia (SCA) causing clinical heterogeneity. Nevertheless, their functional impact on SCA disease emergence and progression remains...
12.
Scopim-Ribeiro R, Machado-Neto J, Eide C, Coelho-Silva J, Fenerich B, Fernandes J, et al.
Invest New Drugs
. 2021 Jan;
39(3):736-746.
PMID: 33403501
Chronic myeloid leukemia (CML) is successfully treated with BCR-ABL1 tyrosine kinase inhibitors, but a significant percentage of patients develop resistance. Insulin receptor substrate 1 (IRS1) has been shown to constitutively...
13.
Carlos J, Lima K, Coelho-Silva J, de Melo Alves-Paiva R, Moreno N, Vicari H, et al.
Cell Oncol (Dordr)
. 2020 Aug;
43(6):1191-1201.
PMID: 32857324
Purpose: Acute lymphoblastic leukemia (ALL) is an aggressive hematological cancer with limited therapeutic options for adult patients. Aurora kinases have drawn attention as potential targets in hematological neoplasms due to...
14.
Fenerich B, Fernandes J, Rodrigues Alves A, Coelho-Silva J, Scopim-Ribeiro R, Scheucher P, et al.
Signal Transduct Target Ther
. 2020 Apr;
5(1):5.
PMID: 32296029
Recent data indicate that IGF1R/IRS signaling is a potential therapeutic target in BCR-ABL1-negative myeloproliferative neoplasms (MPN); in this pathway, IRS2 is involved in the malignant transformation induced by JAK2, and...
15.
Machado-Neto J, Coelho-Silva J, Souza Santos F, Scheucher P, Campregher P, Hamerschlak N, et al.
Invest New Drugs
. 2019 Jul;
38(3):733-745.
PMID: 31286322
JAK2 can mimic growth factor signaling, leading to PI3K/AKT/mTOR activation and inhibition of autophagy. We hypothesized that selective inhibition of JAK1/2 by ruxolitinib could induce autophagy and limit drug efficacy...
16.
Lima K, Coelho-Silva J, Sarti Kinker G, Pereira-Martins D, Traina F, Fernandes P, et al.
Cancer Genet
. 2019 May;
233-234:56-66.
PMID: 31109595
Phosphoinositide signaling pathway orchestrates primordial molecular and cellular functions in both healthy and pathologic conditions. Phosphatidylinositol-5-phosphate 4-kinase type 2 lipid kinase (PIP4K2) family, which compromises PIP4K2A, PIP4K2B and PIP4K2C, has...
17.
Rodrigues Alves A, Fernandes J, Fenerich B, Coelho-Silva J, Scheucher P, Simoes B, et al.
Cancer Lett
. 2019 May;
456:59-68.
PMID: 31042587
The IGF1R/IRS1 signaling is activated in acute lymphoblastic leukemia (ALL) and can be targeted by the pharmacological inhibitors NT157 (IGF1R-IRS1/2 inhibitor) and OSI-906 (IGF1R/IR inhibitor). Here we investigate the cellular...
18.
Machado-Neto J, Fenerich B, Rodrigues Alves A, Fernandes J, Scopim-Ribeiro R, Coelho-Silva J, et al.
Clinics (Sao Paulo)
. 2018 Oct;
73(suppl 1):e566s.
PMID: 30328953
The insulin receptor substrate (IRS) proteins are a family of cytoplasmic proteins that integrate and coordinate the transmission of signals from the extracellular to the intracellular environment via transmembrane receptors,...
19.
Machado-Neto J, Fenerich B, Scopim-Ribeiro R, Eide C, Coelho-Silva J, Dechandt C, et al.
Cell Death Dis
. 2018 Feb;
9(3):311.
PMID: 29472557
The recurrent gain-of-function JAK2 mutation confers growth factor-independent proliferation for hematopoietic cells and is a major contributor to the pathogenesis of myeloproliferative neoplasms (MPN). The lack of complete response in...
20.
Machado-Neto J, Rodrigues Alves A, Fernandes J, Coelho-Silva J, Scopim-Ribeiro R, Fenerich B, et al.
Heliyon
. 2017 Oct;
3(9):e00405.
PMID: 29034341
Acute lymphoblastic leukemia (ALL) is a hematological malignancy characterized by abnormal proliferation and accumulation of lymphoblasts in the hematopoietic system. Stathmin 1 is a proliferation marker for normal lymphocytes, which...